

# Central Nervous System Drug Development

## Neurosciences inclusive of neurology, psychiatry, neuropathic pain and rare diseases

Developing successful central nervous system (CNS) drugs is a complex and ever-evolving process. From conducting lengthy studies and finding specialized sites to completing patient recruitment and meeting strict regulatory guidelines – the challenges can seem endless. That's why you need a clinical development partner that can help you navigate every hurdle.

At IQVIA Biotech, our dedicated teams have extensive CNS experience and relationships around the globe to ensure your clinical trials are completed on time and on budget. We apply scientific, medical and operational expertise coupled with data-driven methods for realistic strategic planning, helping you bring breakthrough CNS drugs to patients, faster.



### Central nervous system - neurosciences

### **Neurology**

- Inflammatory diseases / auto-immune
- Muscular diseases
- Neurodegenerative diseases
- Neuro/orphan/rare diseases
- Peripheral nervous system dysfunction
- Seizure disorders
- Sleep disorders
- Stroke
- Traumatic brain injury



### **Psychiatry**

- · Addiction disorders
- Attention-deficit/ hyperactivity disorder
- Autism
- Bipolar disorders
- Generalized anxiety disorders
- Major depressive disorders
- Post-traumatic stress disorder
- Schizophrenia



### **Pain**

- Migraine
- Neuropathic pain
- Post-herpetic neuralgia
- Trigeminal neuralgia

### Imaging and device

### Diagnostic

- DaT scans
- CT scans
- MRI
- PET scans

### **Therapeutic**

- Deep brain stimulation
- Transmagnetic stimulation
- Vagal nerve stimulation



# ©2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. 09. 2024.BT-BCS2024-2626

### **CHALLENGES OF CNS CLINICAL TRIALS**


Clinical research in CNS disorders is an exciting area as it involves bringing therapies to patients with high unmet medical needs. Indications such as Alzheimer's disease and neuro-orphan diseases remain areas where effective therapies are still lacking. Multiple factors contribute to this highly complex space:

- · High placebo response
- · Lack of specific biomarkers
- · Unknown etiology and pathophysiology
- · Lengthy and complex studies
- · Recruitment challenges
- · Complex study procedures
- · Need for highly specialized sites
- Specific medical and operational sub-specialty approaches

Comprehending the specifics of each therapeutic area requires a large spectrum of expertise that IQVIA Biotech can offer to emerging biopharma companies. Our experts in neuroscience clinical research provide support to help you bring innovative therapies to patients.

### A BIOTECH-SPECIALIZED CRO

IQVIA Biotech delivers flexible clinical solutions designed to help biotech and emerging biopharma companies get treatments to patients, faster. Our proactive and agile team brings over two decades of operational and therapeutic expertise aligned in helping meet your clinical development goals, and essential to successful drug development. We draw on IQVIA's unparalleled data and advanced analytics to create intelligent connections that deliver powerful insights to help visionaries accelerate the clinical development of innovative medical treatments. Contact us to learn how our dedicated CNS team can support your next study.



### Over 1,000 CNS trials in 10 years

WAYS WE CAN HELP	
Protocol validation and optimization	Lab services
Site recruitment and start-up	Safety and pharmacovigilance
Patient recruitment and engagement	Biostatistics
Clinical monitoring (CRAs)	Data management
Project management	Regulatory affairs
eCOA and rater training	Decentralized clinical trials
Medical writing	Connected devices

